3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Anemia
6
Colorectal Neoplasms
3
Anemia, Iron-Deficiency
3
Postoperative Complications
2
Neoplasms
2
Adenocarcinoma
2
Pancreatic Neoplasms
1
Lymphoproliferative Disorders
1
Inflammatory Breast Neoplasms
1
Carcinoma, Ductal, Breast
1
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
ferric carboxymaltose
×
Clear all
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled